A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Hormonal Therapy in Patients With Hormone Receptor (HR)-Positive Localized Inflammatory Breast Cancer (IBC) Who Did Not Achieve a Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Inflammatory breast cancer
- Focus Therapeutic Use
- 06 Feb 2018 Planned End Date changed from 1 Jan 2020 to 1 Jan 2021.
- 26 Jan 2017 Planned primary completion date changed from 1 Dec 2020 to 1 Jan 2020.
- 26 Jan 2017 Status changed from not yet recruiting to recruiting.